Identification of a potential "Hotspot" DNA region in the RUNXI gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation

Tiziana Ottone, Syed Khizer Hasan, Enrico Montefusco, Paola Curzi, Ashley N. Mays, Luciana Chessa, Antonella Ferrari, Esmeralda Conte, Nelida Inés Noguera, Serena Lavorgna, Emanuele Ammatuna, Mariadomenica Divona, Katia Bovetti, Sergio Amadori, David Grimwade, Francesco Lo-Coco

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The translocation t(l6;2l) involving RUNXI (AMLI) and resulting in the RUNXI-CBFA2T3 fusion is a rare but recurrent abnormality mostly found in therapy-related acute myeloid leukemia (t-AML) associated with agents targeting topoisomerase II (topo II). We characterized, at the genomic level, the t(l6;2l) translocation in a patient who developed t-AML after treatment of multiple sclerosis with mitoxantrone (MTZ). Long template nested PCR of genomic DNA followed by direct sequencing enabled the localization of RUNXI and CBFA2T3 (ETO2) breakpoints in introns 5 and 3, respectively. Sequencing of the cDNA with specific primers showed the presence of the expected RUNXI-CBFA2T3 fusion transcript in leukemic cells. The RUNXI intron 5 breakpoint was located at nucleotide position 24,785. This region contained an ATGCCCCAG nucleotide sequence showing ∼90% homology to a "hotspot" DNA region ATGCCCTAG present in intron 6 of PML previously identified in therapy-related acute promyelocytic leukemia cases arising following treatment with MTZ. This study suggests a wider distribution in the human genome, and particularly at genes involved in chromosome translocations observed in t-AML, of DNA regions (hotspot) targeted by specific topo II drugs.

Original languageEnglish
Pages (from-to)213-221
Number of pages9
JournalGenes Chromosomes and Cancer
Volume48
Issue number3
DOIs
Publication statusPublished - Mar 2009

Fingerprint

Mitoxantrone
Acute Myeloid Leukemia
DNA
Introns
Genes
Type II DNA Topoisomerase
Therapeutics
Acute Promyelocytic Leukemia
Human Genome
Multiple Sclerosis
Nucleotides
Complementary DNA
Chromosomes
Polymerase Chain Reaction
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Identification of a potential "Hotspot" DNA region in the RUNXI gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation. / Ottone, Tiziana; Hasan, Syed Khizer; Montefusco, Enrico; Curzi, Paola; Mays, Ashley N.; Chessa, Luciana; Ferrari, Antonella; Conte, Esmeralda; Noguera, Nelida Inés; Lavorgna, Serena; Ammatuna, Emanuele; Divona, Mariadomenica; Bovetti, Katia; Amadori, Sergio; Grimwade, David; Lo-Coco, Francesco.

In: Genes Chromosomes and Cancer, Vol. 48, No. 3, 03.2009, p. 213-221.

Research output: Contribution to journalArticle

Ottone, T, Hasan, SK, Montefusco, E, Curzi, P, Mays, AN, Chessa, L, Ferrari, A, Conte, E, Noguera, NI, Lavorgna, S, Ammatuna, E, Divona, M, Bovetti, K, Amadori, S, Grimwade, D & Lo-Coco, F 2009, 'Identification of a potential "Hotspot" DNA region in the RUNXI gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation', Genes Chromosomes and Cancer, vol. 48, no. 3, pp. 213-221. https://doi.org/10.1002/gcc.20633
Ottone, Tiziana ; Hasan, Syed Khizer ; Montefusco, Enrico ; Curzi, Paola ; Mays, Ashley N. ; Chessa, Luciana ; Ferrari, Antonella ; Conte, Esmeralda ; Noguera, Nelida Inés ; Lavorgna, Serena ; Ammatuna, Emanuele ; Divona, Mariadomenica ; Bovetti, Katia ; Amadori, Sergio ; Grimwade, David ; Lo-Coco, Francesco. / Identification of a potential "Hotspot" DNA region in the RUNXI gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation. In: Genes Chromosomes and Cancer. 2009 ; Vol. 48, No. 3. pp. 213-221.
@article{06fb5eccfaa042ffa48de7d12a4eb186,
title = "Identification of a potential {"}Hotspot{"} DNA region in the RUNXI gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation",
abstract = "The translocation t(l6;2l) involving RUNXI (AMLI) and resulting in the RUNXI-CBFA2T3 fusion is a rare but recurrent abnormality mostly found in therapy-related acute myeloid leukemia (t-AML) associated with agents targeting topoisomerase II (topo II). We characterized, at the genomic level, the t(l6;2l) translocation in a patient who developed t-AML after treatment of multiple sclerosis with mitoxantrone (MTZ). Long template nested PCR of genomic DNA followed by direct sequencing enabled the localization of RUNXI and CBFA2T3 (ETO2) breakpoints in introns 5 and 3, respectively. Sequencing of the cDNA with specific primers showed the presence of the expected RUNXI-CBFA2T3 fusion transcript in leukemic cells. The RUNXI intron 5 breakpoint was located at nucleotide position 24,785. This region contained an ATGCCCCAG nucleotide sequence showing ∼90{\%} homology to a {"}hotspot{"} DNA region ATGCCCTAG present in intron 6 of PML previously identified in therapy-related acute promyelocytic leukemia cases arising following treatment with MTZ. This study suggests a wider distribution in the human genome, and particularly at genes involved in chromosome translocations observed in t-AML, of DNA regions (hotspot) targeted by specific topo II drugs.",
author = "Tiziana Ottone and Hasan, {Syed Khizer} and Enrico Montefusco and Paola Curzi and Mays, {Ashley N.} and Luciana Chessa and Antonella Ferrari and Esmeralda Conte and Noguera, {Nelida In{\'e}s} and Serena Lavorgna and Emanuele Ammatuna and Mariadomenica Divona and Katia Bovetti and Sergio Amadori and David Grimwade and Francesco Lo-Coco",
year = "2009",
month = "3",
doi = "10.1002/gcc.20633",
language = "English",
volume = "48",
pages = "213--221",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Identification of a potential "Hotspot" DNA region in the RUNXI gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation

AU - Ottone, Tiziana

AU - Hasan, Syed Khizer

AU - Montefusco, Enrico

AU - Curzi, Paola

AU - Mays, Ashley N.

AU - Chessa, Luciana

AU - Ferrari, Antonella

AU - Conte, Esmeralda

AU - Noguera, Nelida Inés

AU - Lavorgna, Serena

AU - Ammatuna, Emanuele

AU - Divona, Mariadomenica

AU - Bovetti, Katia

AU - Amadori, Sergio

AU - Grimwade, David

AU - Lo-Coco, Francesco

PY - 2009/3

Y1 - 2009/3

N2 - The translocation t(l6;2l) involving RUNXI (AMLI) and resulting in the RUNXI-CBFA2T3 fusion is a rare but recurrent abnormality mostly found in therapy-related acute myeloid leukemia (t-AML) associated with agents targeting topoisomerase II (topo II). We characterized, at the genomic level, the t(l6;2l) translocation in a patient who developed t-AML after treatment of multiple sclerosis with mitoxantrone (MTZ). Long template nested PCR of genomic DNA followed by direct sequencing enabled the localization of RUNXI and CBFA2T3 (ETO2) breakpoints in introns 5 and 3, respectively. Sequencing of the cDNA with specific primers showed the presence of the expected RUNXI-CBFA2T3 fusion transcript in leukemic cells. The RUNXI intron 5 breakpoint was located at nucleotide position 24,785. This region contained an ATGCCCCAG nucleotide sequence showing ∼90% homology to a "hotspot" DNA region ATGCCCTAG present in intron 6 of PML previously identified in therapy-related acute promyelocytic leukemia cases arising following treatment with MTZ. This study suggests a wider distribution in the human genome, and particularly at genes involved in chromosome translocations observed in t-AML, of DNA regions (hotspot) targeted by specific topo II drugs.

AB - The translocation t(l6;2l) involving RUNXI (AMLI) and resulting in the RUNXI-CBFA2T3 fusion is a rare but recurrent abnormality mostly found in therapy-related acute myeloid leukemia (t-AML) associated with agents targeting topoisomerase II (topo II). We characterized, at the genomic level, the t(l6;2l) translocation in a patient who developed t-AML after treatment of multiple sclerosis with mitoxantrone (MTZ). Long template nested PCR of genomic DNA followed by direct sequencing enabled the localization of RUNXI and CBFA2T3 (ETO2) breakpoints in introns 5 and 3, respectively. Sequencing of the cDNA with specific primers showed the presence of the expected RUNXI-CBFA2T3 fusion transcript in leukemic cells. The RUNXI intron 5 breakpoint was located at nucleotide position 24,785. This region contained an ATGCCCCAG nucleotide sequence showing ∼90% homology to a "hotspot" DNA region ATGCCCTAG present in intron 6 of PML previously identified in therapy-related acute promyelocytic leukemia cases arising following treatment with MTZ. This study suggests a wider distribution in the human genome, and particularly at genes involved in chromosome translocations observed in t-AML, of DNA regions (hotspot) targeted by specific topo II drugs.

UR - http://www.scopus.com/inward/record.url?scp=62449145322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62449145322&partnerID=8YFLogxK

U2 - 10.1002/gcc.20633

DO - 10.1002/gcc.20633

M3 - Article

VL - 48

SP - 213

EP - 221

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 3

ER -